MeiraGTx Holdings plc entered into Amendments extending the maturity of its Notes Purchase Agreement from August 2, 2026 to May 2, 2027, agreeing to redeem $25 million principal by June 30, 2026, and reducing warrant exercise prices to $8.00 per share. The company reported 2025 financial results including $81.4 million revenue and $68.2 million cash, plus FDA Breakthrough Therapy Designation for AAV2-hAQP1.
Key takeaways
Amendments to Notes Purchase Agreement extend maturity to May 2, 2027 and require $25 million principal redemption by June 30, 2026
Warrants amended to $8.00 exercise price for 700,000 ordinary shares
FDA Breakthrough Therapy Designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia
License revenue $75.0 million from Lilly collaboration in 2025
Cash and equivalents $68.2 million as of December 31, 2025
Hologen joint venture with $200 million upfront and up to $230 million committed funding